Abstract
rate in the late-onset group tended to be lower than that in the early-onset group. In particular, the resection rate was significantly lower in patients with the perforating type in the late-onset group (12.5%) compared to the early-onset group (21.3%). (3) Multivariate analysis revealed that absence of anti-TNF-a therapy was a sole risk factor for surgery. (4) The cumulative resection rate over 5 years was significantly lower in patients receiving anti-TNF-a therapy than in those not receiving this therapy, based on a background-matched analysis between the 2 groups (30.0% vs. 17.7%). In addition, the early initiation of anti-TNF-a therapy (within 3 years of disease onset) resulted in a decreased resection rate compared with late initiation of anti-TNF-a therapy (3 or more years after disease onset). Conclusions: Anti-TNF-a therapy was effective at preventing surgery for intestinal complications of Crohn’s disease.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
